Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart As The Core Immunosuppressant

Reuters
2025.11.18 21:36
Nov 18 (Reuters) - Eledon Pharmaceuticals Inc (ELDN.O) : * ELEDON REPORTS PRELIMINARY DATA FROM FIRST SIX PATIENTS WITH TYPE 1 DIABETES TREATED WITH TEGOPRUBART AS THE CORE IMMUNOSUPPRESSANT FOLLOWING ISLET TRANSPLANTATION IN INVESTIGATOR-INITIATED TRIAL AT UCHICAGO MEDICINE * ELEDON PHARMACEUTICALS INC - TEGOPRUBART WELL TOLERATED, NO SERIOUS INFECTIONS OR REJECTION EVENTS Source text: Further company coverage: (ELDN.O)
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.